SCHEMBL17265472

SCHEMBL17265472

CCOC(=O)CCc1ccc(-c2ccc(-c3onc(C)c3C(COCc3cccc(C(F)(F)F)c3)OC)cc2)cc1

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ FFAR1 O14842 3/20 0.39
▸ FFAR4 Q5NUL3 2/20 0.39
▸ SYK P43405 3/20 0.36
▸ KMT2A Q03164 2/20 0.36
▸ MEN1 O00255 1/20 0.36
▸ THRB P10828 2/20 0.35
▸ EGLN1 Q9GZT9 1/20 0.35
▸ MAPT P10636 2/20 0.35
▸ ANO1 Q5XXA6 1/20 0.35
▸ THRA P10827 1/20 0.34
▸ TDP1 Q9NUW8 1/20 0.34
▸ EPHX2 P34913 1/20 0.34
▸ PPARG P37231 1/20 0.34
▸ PPARD Q03181 1/20 0.34
▸ PPARA Q07869 1/20 0.34
▸ LTB4R2 Q9NPC1 1/20 0.34
▸ ALDH1A1 P00352 1/20 0.33
▸ SMN1; SMN2 Q16637 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17265470 0.92 SYK (0.38) SYKKMT2AMEN1THRBEGLN1
SCHEMBL17265473 0.91 FFAR1 (0.48) FFAR1FFAR4THRBEGLN1ANO1
SCHEMBL6868 0.91 FFAR1 (0.40) FFAR1FFAR4SYKKMT2AMEN1
SCHEMBL17265471 0.86 LPAR1 (0.41) FFAR1FFAR4EGLN1ANO1PPARG
SCHEMBL17265476 0.86 MEN1 (0.36) KMT2AMEN1THRBEGLN1MAPT
SCHEMBL17265474 0.85 MEN1 (0.37) KMT2AMEN1EGLN1ANO1TDP1
SCHEMBL17265469 0.83 NR1H4 (0.37) EGLN1ANO1
SCHEMBL6659 0.83 MEN1 (0.40) SYKKMT2AMEN1THRBEGLN1
SCHEMBL17265475 0.82 LPAR1 (0.43) KMT2AMEN1EGLN1MAPTANO1
SCHEMBL6614 0.82 FFAR1 (0.50) FFAR1FFAR4THRBEGLN1ANO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9624182-B2 Compounds as lysophosphatidic acid receptor antagonists AMIRA PHARMACEUTICALS, INC. (US) 2017-04-18 — — US disclosed
US-20150329502-A1 COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS AMIRA PHARMACEUTICALS, INC. (US) 2015-11-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150329502-A1 COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS LPAR1, LPAR2, LPAR4 FFAR1 22/4885FFAR4 39/4885SYK 2738/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback